These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 12441042)

  • 1. Treatment of the extraintestinal manifestations of inflammatory bowel disease.
    Bernstein CN
    Curr Gastroenterol Rep; 2002 Dec; 4(6):513-6. PubMed ID: 12441042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].
    Kujundzić M
    Acta Med Croatica; 2013 Apr; 67(2):195-201. PubMed ID: 24471303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of extraintestinal manifestations in inflammatory bowel disease.
    Lakatos PL; Lakatos L; Kiss LS; Peyrin-Biroulet L; Schoepfer A; Vavricka S
    Digestion; 2012; 86 Suppl 1():28-35. PubMed ID: 23051724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Infliximab for the management of pyoderma gangrenosum in inflammatory bowel disease: one for all?].
    Tanczos BT; Baumgart DC
    Z Gastroenterol; 2006 Jul; 44(7):609-10. PubMed ID: 16823703
    [No Abstract]   [Full Text] [Related]  

  • 5. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.
    Bernstein CN; Blanchard JF; Rawsthorne P; Yu N
    Am J Gastroenterol; 2001 Apr; 96(4):1116-22. PubMed ID: 11316157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.
    Barrie A; Regueiro M
    Inflamm Bowel Dis; 2007 Nov; 13(11):1424-9. PubMed ID: 17567879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do extraintestinal manifestations predict disease course, severity, and/or activity in IBD?
    Walker D; Orchard T
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S200-1. PubMed ID: 18816647
    [No Abstract]   [Full Text] [Related]  

  • 9. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum.
    Triantafillidis JK; Cheracakis P; Sklavaina M; Apostolopoulou K
    Scand J Gastroenterol; 2002 Jul; 37(7):863-5. PubMed ID: 12190104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease.
    Reguiaï Z; Grange F
    Am J Clin Dermatol; 2007; 8(2):67-77. PubMed ID: 17428111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extraintestinal manifestations of Crohn's disease.
    Juillerat P; Mottet C; Pittet V; Froehlich F; Felley C; Gonvers JJ; Vader JP; Michetti P
    Digestion; 2007; 76(2):141-8. PubMed ID: 18239406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics for extraintestinal manifestations of IBD.
    Vavricka SR; Scharl M; Gubler M; Rogler G
    Curr Drug Targets; 2014; 15(11):1064-73. PubMed ID: 25198785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.
    Regueiro M; Valentine J; Plevy S; Fleisher MR; Lichtenstein GR
    Am J Gastroenterol; 2003 Aug; 98(8):1821-6. PubMed ID: 12907338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extraintestinal manifestations of inflammatory bowel disease.
    Bernstein CN
    Curr Gastroenterol Rep; 2001 Dec; 3(6):477-83. PubMed ID: 11696285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extraintestinal manifestations of Crohn's disease.
    Juillerat P; Mottet C; Froehlich F; Felley C; Vader JP; Burnand B; Gonvers JJ; Michetti P
    Digestion; 2005; 71(1):31-6. PubMed ID: 15711047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How prevalent are extraintestinal manifestations at the initial diagnosis of IBD?
    Isaacs KL
    Inflamm Bowel Dis; 2008 Oct; 14 Suppl 2():S198-9. PubMed ID: 18816779
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series.
    Altwegg R; Combes R; Laharie D; De Ledinghen V; Radenne S; Conti F; Chazouilleres O; Duvoux C; Dumortier J; Leroy V; Treton X; Durand F; Dharancy S; Nachury M; Goutorbe F; Lamblin G; Boivineau L; Peyrin-Biroulet L; Pageaux GP
    Dig Liver Dis; 2018 Jul; 50(7):668-674. PubMed ID: 29655972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review: IBD-associated pyoderma gangrenosum in the biologic era, the response to therapy.
    Agarwal A; Andrews JM
    Aliment Pharmacol Ther; 2013 Sep; 38(6):563-72. PubMed ID: 23914999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of anti-TNFalpha treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis.
    Verschueren P; Lensen F; Lerut E; Claes K; De Vos R; Van Damme B; Westhovens R
    Ann Rheum Dis; 2003 Apr; 62(4):368-9. PubMed ID: 12634242
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.